Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2026TH OpenOpen Access

Efficacy and safety of avatrombopag treatment in immune thrombocytopenia patients in Poland: a multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMichal WitkowskiLodz University of TechnologyJRJagoda RytelMedical University of WarsawJKJustyna KozińskaMedical University of Lublin

Discussion

Loading...

Member takes

Overview

Retrospective multicenter study shows high efficacy and safety of avatrombopag in Polish adults with ITP, indicating potential for treatment de-escalation.

Key Points

  • To evaluate the real-world efficacy, safety, and treatment-free remission of avatrombopag in Polish adults with immune thrombocytopenia.
  • Conducted a retrospective multicenter study across eight hematology centers in Poland.
  • Included 142 adults with primary immune thrombocytopenia treated with avatrombopag.
  • Assessed responses at 1, 3, 6, and 12 months using International Working Group criteria.
  • 78.3% achieved a platelet response by month 1, including 47.8% with complete response.
  • Response rates increased to 84.1%, 90.8%, and 96.8% at 3, 6, and 12 months, respectively.
  • 2.8% achieved treatment-free remission following discontinuation.

Cite This Study

Witkowski et al. (2026) studied this question.

synapsesocial.com/papers/69fc2ca48b49bacb8b348158https://doi.org/10.1055/a-2868-3290
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag2026
  2. 2Galician-Asturian experience of avatrombopag use in immune thrombocytopenia2025
  3. 3Real-World Insights into Avatrombopag’s Effectiveness and Safety in Adults with Primary Immune Thrombocytopenia: A Retrospective Analysis from Central and Eastern Europe2025 · 1 citations
  4. 4Successful Management of Relapsed Severe Immune Thrombocytopenia Using Avatrombopag: A Case Report2026
  5. 5Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial2026